Jasper Therapeutics Inc JSPR Stock Analysis
- Nasdaq
- Stock
- Market closed · opens Monday 9:30 AM ET
$16.86 up $2.78, 19.78% at close Nov 6
Last close · Previous close $14.08
JSPR split 1-for-30 on ; earlier prices are adjusted for it.
- Market cap
- $472.03MAt the Nov 6 close
- P/E ratio
- PausedOn last 12 months’ EPS
See the note under the price. - Diluted EPS
- PausedLast 12 months
See the note under the price. - Dividend yield
- NoneLast 12 months
Price chart
$16.86up $0.06, 0.34%Past month
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$14.08Nov 5
- Volume63.25KNov 6 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume16.86KLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $9.45 to $72.60; now $16.86
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Nov 6 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
JSPR beat the S&P 500 in 1 of 6 periods.
| Period | JSPR and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | JSPR: up 0.3% S&P 500: down 5.6% | JSPR beat the S&P 500 by 5.9 percentage points Beat |
| 3M | JSPR: down 13.0% S&P 500: down 4.1% | JSPR trailed the S&P 500 by 8.9 percentage points Trailed |
| YTD | JSPR: down 69.3% S&P 500: up 8.7% | JSPR trailed the S&P 500 by 78.0 percentage points Trailed |
| 1Y | JSPR: down 69.3% S&P 500: up 10.9% | JSPR trailed the S&P 500 by 80.2 percentage points Trailed |
| Long term | ||
| 3Y | JSPR: down 93.0% S&P 500: up 75.0% −58.7% vs +20.5% a year | JSPR trailed the S&P 500 by 168.0 percentage points Trailed |
| 5Y | JSPR: down 99.4% S&P 500: up 67.8% −64.0% vs +10.9% a year | JSPR trailed the S&P 500 by 167.2 percentage points Trailed |
$10,000 invested in JSPR 5 years ago (Nov 5, 2021) would be worth about $61 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $16,782.
JSPR beat the S&P 500 in 1 of 6 periods.
| Period | JSPR and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | JSPR: up 0.3% S&P 500: down 5.6% | JSPR beat the S&P 500 by 5.9 percentage points Beat |
| 3M | JSPR: down 13.0% S&P 500: down 4.3% | JSPR trailed the S&P 500 by 8.7 percentage points Trailed |
| YTD | JSPR: down 69.3% S&P 500: up 7.8% | JSPR trailed the S&P 500 by 77.1 percentage points Trailed |
| 1Y | JSPR: down 69.3% S&P 500: up 9.7% | JSPR trailed the S&P 500 by 79.0 percentage points Trailed |
| Long term | ||
| 3Y | JSPR: down 93.0% S&P 500: up 68.8% −58.7% vs +19.1% a year | JSPR trailed the S&P 500 by 161.8 percentage points Trailed |
| 5Y | JSPR: down 99.4% S&P 500: up 56.9% −64.0% vs +9.4% a year | JSPR trailed the S&P 500 by 156.3 percentage points Trailed |
$10,000 invested in JSPR 5 years ago (Nov 5, 2021) would be worth about $61 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $15,694.
All-time high
$4,926.00
Closing high on . Now 99.7% below that record.
Split-adjusted daily closes since Sep 24, 2021.
Stock splits
2
Latest: 1-for-30 on . Share counts adjust after each split.
Both splits
- 1-for-30
- 1-for-10
Valuation
The Nov 6 close compared with the last 12 months of reported results (the four quarters to Jun 30, 2026). Tap a metric to see how it’s calculated. Per-share results and the measures based on them are paused. See the note under the price.
Price-to-earnings (P/E)
Paused
Other valuation measures
- Price-to-bookPausedBook value as of Jun 30, 2026
See the note under the price. - PEG ratioPausedLast 12 months’ EPS growth
See the note under the price. - −12.76%Last 12 months’ free cash flow
Free cash flow over the last 12 months as a share of the company’s market value: the cash the business generated for each dollar of stock.
FCF yield = Free cash flow (last 12 months) ÷ Market capFree cash flow - $464.57MAt the Nov 6 close
What it would cost to buy the whole business: the market cap at the Nov 6 close, plus debt, minus cash and short-term investments from the Jun 30, 2026 balance sheet.
EV = Market cap + Debt − Cash and short-term investmentsEV/EBITDA explained
Build your own JSPR DCF in Excel. Value Jasper Therapeutics with your own growth and margin assumptions.Browse DCF models Free DCF calculator
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q2 FY26, the quarter ended Jun 30, 2026. “Last 12 months” means the four quarters from Jul 1, 2025 to Jun 30, 2026, and balance-sheet figures are as of Jun 30, 2026.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $0.00
- Net income
- −$31.77M
- Diluted EPS
- PausedSee the note under the price.
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q3 FY24 (Sep 30, 2024) | $0.00 | −$18.64M | Paused See the note under the price. |
| Q4 FY24 (Dec 31, 2024) | $0.00 | −$24.32M | Paused See the note under the price. |
| Q1 FY25 (Mar 31, 2025) | $0.00 | −$21.24M | Paused See the note under the price. |
| Q2 FY25 (Jun 30, 2025) | $0.00 | −$26.72M | Paused See the note under the price. |
| Q3 FY25 (Sep 30, 2025) | $0.00 | −$18.74M | Paused See the note under the price. |
| Q4 FY25 (Dec 31, 2025) | $0.00 | −$9.10M | Paused See the note under the price. |
| Q1 FY26 (Mar 31, 2026) | $0.00 | −$1.17M | Paused See the note under the price. |
| Q2 FY26 (Jun 30, 2026) | $0.00 | −$2.76M | Paused See the note under the price. |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY21 (Dec 31, 2021) | $0.00 | −$30.64M | Paused See the note under the price. |
| FY22 (Dec 31, 2022) | $0.00 | −$37.69M | Paused See the note under the price. |
| FY23 (Dec 31, 2023) | $0.00 | −$64.47M | Paused See the note under the price. |
| FY24 (Dec 31, 2024) | $0.00 | −$71.27M | Paused See the note under the price. |
| FY25 (Dec 31, 2025) | $0.00 | −$75.80M | Paused See the note under the price. |
Margins
- Gross —
- Operating —
- Net —
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- −$60.25MLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow−$60.33MLast 12 months
- Capital spending$80.00KLast 12 months
Shareholder returns
- $28.05MLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paid$0.00Last 12 months
- Total returned$0.00Last 12 months
Balance sheet
- $7.73MAs of Jun 30, 2026
Cash plus short- and long-term marketable securities on the Jun 30, 2026 balance sheet.
- Total debt$270.00KAs of Jun 30, 2026
- Net cash$7.46MAs of Jun 30, 2026
- Book value per sharePausedAs of Jun 30, 2026
See the note under the price. - 1.47As of Jun 30, 2026
Current assets divided by current liabilities on the Jun 30, 2026 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio - 0.19As of Jun 30, 2026
Total debt divided by shareholders’ equity on the Jun 30, 2026 balance sheet: a measure of financial leverage.
D/E = Total debt ÷ Shareholders’ equityDebt-to-equity ratio
Financial strength
- −618.9%Last 12 months
Over the last 12 months, Jasper Therapeutics lost money: its net loss was 618.9% of its shareholders’ equity (averaged over the last four quarter-ends). It describes the past year, not an expected return.
ROE = Net income (last 12 months) ÷ Average equityReturn on equity - −100.7%Last 12 months
Over the last 12 months, Jasper Therapeutics’s net loss was 100.7% of its total assets (averaged over the last four quarter-ends).
ROA = Net income (last 12 months) ÷ Average total assets
About Jasper Therapeutics Inc
Jasper Therapeutics, Inc. is a biotechnology company focused on the development of novel curative therapies based on the biology of the hematopoietic stem cell. The company is advancing two potentially groundbreaking programs. JSP191, an anti-CD117 monoclonal antibody, is in clinical development as a conditioning agent that clears hematopoietic stem cells from bone marrow in patients undergoing a hematopoietic cell transplantation. It is designed to enable safer and more effective curative allogeneic hematopoietic cell transplants and gene therapies. Jasper is also advancing JSP191 as a potential therapeutic for patients with lower risk Myelodysplastic Syndrome (MDS). Jasper Therapeutics is also advancing its preclinical mRNA hematopoietic stem cell graft platform, which is designed to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. Both innovative programs have the potential to transform the field and expand hematopoietic stem cell therapy cures to a greater number of patients with life-threatening cancers, genetic diseases and autoimmune diseases than is possible today.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- California, USA
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
JSPR news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
JSPR stock FAQ
What is JSPR stock’s price today?
Jasper Therapeutics (JSPR) traded at $16.86 at the close on , up $2.78 (19.78%) from the previous close of $14.08. Over the past 52 weeks it has traded between $9.45 and $72.60.
If you invested $1,000 in JSPR 5 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in JSPR on would be worth about $6 at the close on , a total return of −99.4%. The same $1,000 would be worth $307 if invested one year ago. Past performance doesn’t predict future returns.
What is Jasper Therapeutics’s market cap?
Jasper Therapeutics’s market capitalization is about $472.0 million. That’s Tiingo’s daily market cap for , at that day’s closing price of $16.86 (how market cap works).
Does JSPR pay a dividend?
Jasper Therapeutics hasn’t paid a dividend in the last twelve months.
What is JSPR’s 52-week high and low?
Over the past 52 weeks JSPR has traded as low as $9.45 and as high as $72.60. At $16.86 at the close on , it is 76.8% below that high and 78.4% above the low.
What is JSPR’s all-time high?
JSPR’s highest closing price was $4,926.00 on , adjusted for stock splits. At $16.86 at the close on , it is 99.7% below that record.
Has JSPR stock ever split?
Yes, twice: 1-for-10 on ; 1-for-30 on .
How has JSPR stock performed?
Including dividends and measured to the close on , JSPR has returned −69.3% so far this year and −69.3% over the past year, and −99.4% over five years (−64.0% a year). Over the same periods the S&P 500, measured by SPY, returned +8.7%, +10.9% and +67.8%. Past performance doesn’t predict future returns.
What sector and industry is Jasper Therapeutics in?
Jasper Therapeutics is in the Healthcare sector and the Biotechnology industry, and is headquartered in California, USA.
What exchange does JSPR trade on?
Jasper Therapeutics trades on the Nasdaq under the ticker symbol JSPR. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.